CRISPR Therapeutics
CRSP
CRSP
310 hedge funds and large institutions have $4B invested in CRISPR Therapeutics in 2020 Q3 according to their latest regulatory filings, with 69 funds opening new positions, 96 increasing their positions, 86 reducing their positions, and 32 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
12% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 86
3.78% more ownership
Funds ownership: 64.46% → 68.24% (+3.8%)
3% less call options, than puts
Call options by funds: $64.7M | Put options by funds: $66.4M
Holders
310
Holding in Top 10
9
Calls
$64.7M
Puts
$66.4M
Top Buyers
| 1 | +$572M | |
| 2 | +$165M | |
| 3 | +$112M | |
| 4 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$23.9M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$21.4M |
Top Sellers
| 1 | -$46.1M | |
| 2 | -$41.9M | |
| 3 | -$36.4M | |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$25.9M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$24.9M |